Latest Chemotherapy regimens Stories
NEW YORK, Feb. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S.
Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm QUEBEC CITY, Jan. 25 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Long-term Results in both First-line and Refractory Settings Seen in Patients with Non-Hodgkin's Lymphoma PHILADELPHIA, Dec.
There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.
NEW ORLEANS, Dec.
Finland, November 11 /PRNewswire/ -- - This is a third party press release.
U.S. medical scientists say they have developed a new chemotherapy regimen for pediatric Hodgkin's lymphoma patients. Dr.
MALVERN, Pa., June 1 /PRNewswire/ -- Ascenta Therapeutics announced today that promising results from ongoing clinical studies in prostate, brain and lung cancers were among the data presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida.
Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
NCCN presented new NCCN Clinical Practice Guidelines in Oncology(TM) for Primary Cutaneous B-Cell Lymphoma as well as important updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas at the NCCN 14th Annual Conference.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.